The future of pulmonary hypertension

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Rapidly evolving understanding of pulmonary vascular pathophysiology, pathways of vascular proliferation and remodeling, right ventricular adaptation and maladaptation, and right ventricular to pulmonary artery coupling have set the stage for an exciting future in the treatment of pulmonary arterial hypertension. Network biology, informatics, and the revolution in genomics, proteomics, and metabolomics promise even more advances in the years ahead. Combined with burgeoning availability of vasodilator therapy and ability to quantitate right ventricular function, this new understanding is poised to revolutionize therapeutic strategies. This chapter details the nature of these developments and provides perspective on the most promising approaches. The importance of proper clinical trial design, innovations in surrogate endpoints to guide phase II trial efficiency, and the need for collaboration across academia, clinical centers, the pharmaceutical industry and the private sector is emphasized.

Original languageEnglish (US)
Title of host publicationPulmonary Hypertension: Basic Science to Clinical Medicine
PublisherSpringer International Publishing
Pages359-367
Number of pages9
ISBN (Electronic)9783319235943
ISBN (Print)9783319235936
DOIs
StatePublished - Jan 1 2015

Keywords

  • Antiproliferative therapy
  • Genomics
  • Hemodynamics
  • Network biology
  • Pulmonary arterial hypertension
  • Right heart failure
  • Vascular remodeling

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The future of pulmonary hypertension'. Together they form a unique fingerprint.

Cite this